Covalent Immunology Prod Inc is categorized under Biological Research in Houston, TX and active since 2009.
Covalent Immunology Prod Inc was established in 2009, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Biological Research business, which does work in the B2B market, and is classified as a Biological Research, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Benjamin Adler, Chief Executive Officer at the company’s single location by writing to 8011 Candle Lane, Houston, Texas TX 77071 or by phoning (713) 270-5391. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Covalent Immunology Prod Inc |
| Contact Person: | Benjamin Adler, Chief Executive Officer |
| Address: | 8011 Candle Lane, Houston, Texas 77071 |
| Phone Number: | (713) 270-5391 |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 2009 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Biological Research |
| SIC Code: | 8731 |
| NAICS Code: | 6211110 |
| Share This Business: |
Covalent Immunology Prod Inc was started in 2009 to provide professional Biological Research under the SIC code 8731 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Benjamin Adler, Chief Executive Officer for inquiries that concern Covalent Immunology Prod Inc by calling the company number (713) 270-5391, as your correspondence is most welcome. Additionally, the physical location of the single location of Covalent Immunology Prod Inc can be found at the coordinates 29.65916,-95.519243 as well as the street address 8011 Candle Lane in Houston, Texas 77071.
For its online presence, you may visit Covalent Immunology Prod Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.